{"id":904001,"date":"2025-11-03T08:26:35","date_gmt":"2025-11-03T13:26:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/"},"modified":"2025-11-03T08:26:35","modified_gmt":"2025-11-03T13:26:35","slug":"eyepoint-announces-participation-at-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/","title":{"rendered":"EyePoint Announces Participation at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WATERTOWN, Mass., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt;margin-bottom:8pt;text-align:justify\">\n          <strong>Guggenheim\u2019s 2<\/strong><br \/>\n          <sup><br \/>\n            <strong>nd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Healthcare Innovation Conference<\/strong><br \/>\n          <br \/>Forum: Fireside Chat<br \/>Date: Monday, November 10, 2025<br \/>Time: 10:30 a.m. ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt;margin-bottom:8pt;text-align:justify\">\n          <strong>Stifel 2025 Healthcare Conference<\/strong><br \/>\n          <br \/>Forum: Corporate Presentation<br \/>Date: Wednesday, November 12, 2025<br \/>Time: 10:40 a.m. ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt;margin-bottom:8pt;text-align:justify\">\n          <strong>Jefferies London Healthcare Conference<\/strong><br \/>\n          <br \/>Forum: 1&#215;1 Investor Meetings<br \/>Date: Monday, November 17, 2025<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vARQliRYsy4tLEOFveIauY-Rwx8Xu2PKWZGVVhbbY8XGPXVFgfLGr1EaDWsyV5NmrdxkEqaqOf7S_GgiPiMNd5y12HtknFFtFJbaAnUSajbQK3A4EgWfW_IegqH9RtMa00fyF-fBoEga9g70eaeeFEDDX-MUSDkYydbj1jl899uoS4f79v8C993_FN2ZkiwdBrAHJlG4aWSzdokUGrqg8z5RCqvQJD1vEkWyQ_efhJN3cCQMS8ODKIW9RKmVF7Mm6n3rSIxiCN8fE3UhKiR8JA==\" rel=\"nofollow\" target=\"_blank\">www.eyepointpharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About EyePoint<\/strong>\n      <\/p>\n<p>EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company\u2019s lead product candidate, DURAVYU<sup>\u2122<\/sup>, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E<sup>\u2122<\/sup> technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.<\/p>\n<p>The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.<\/p>\n<p>EyePoint is headquartered in\u00a0Watertown, Massachusetts, with a commercial manufacturing facility in\u00a0Northbridge, Massachusetts.<\/p>\n<p>Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of\u00a0China,\u00a0Macao,\u00a0Hong Kong\u00a0and\u00a0Taiwan.<\/p>\n<p>\n        <em>DURAVYU<\/em><br \/>\n        <sup><br \/>\n          <em>\u2122<\/em><br \/>\n        <\/sup><br \/>\n        <em>\u00a0has been conditionally accepted by the FDA as the proprietary name for EYP-1901 (vorolanib intravitreal insert). DURAVYU is an investigational medicinal product and is not authorized for sale in any country at the present time. FDA approval in the United States and marketing authorization in any other country and the timeline for potential approval or authorization is uncertain.<\/em>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong>\n      <\/p>\n<p>Tanner Kaufman \/ Jenni Lu<br \/>FTI Consulting <br \/>Direct: 203-722-8743 \/ 667-321-6018<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8PNIvslFzOXbq3hIfV9lS1Lx1x88MZDlAovmtYs8gJ9nAyPl14p7qraMHjnD2qnQM1GGLskb7JOFbxN16SjBdg2b7EvWPAMCoj0JErZ_pdXsrcsxGP9a_wV2uA5Guhs_UkmJDNfvuv-EM_WLbzOE7Q==\" rel=\"nofollow\" target=\"_blank\">tanner.kaufman@fticonsulting.com<\/a> \/ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K7Ym8NXFj02N7h5oVxVZnqVs0c67nE2hjfAnvPLKCJwFW7pjafAVvwvEOjYnfyK6o5VjfKRGjFf6wly2KtctMjcB9wVhF04pMvsw9FCjStCxm3dJj1aCZTeVbSY76_xz\" rel=\"nofollow\" target=\"_blank\">jenni.lu@fticonsulting.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Amy Phillips<br \/>Green Room Communications<br \/>Direct: 412-327-9499<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vlNhxeH-U4xwmCACPh4ocwLM2hNVQTykKDc1W5G9dhAmNjd9AHKDQL0DM06diDQRdqBbo7OrsXg0-VtzHijlJCJhzZSwVfkYeTnqP-O0QzMK_yn3mn6o8ISi7Ghm2Zo1\" rel=\"nofollow\" target=\"_blank\">aphillips@greenroompr.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDE2YTJhODYtYzE3YS00ZWY2LWJiYzItYWM5YmJjNGE1MTBhLTEwMTczOTAtMjAyNS0xMS0wMy1lbg==\/tiny\/EyePoint-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Guggenheim\u2019s 2 nd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: Monday, November 10, 2025Time: 10:30 a.m. ET Stifel 2025 Healthcare Conference Forum: Corporate PresentationDate: Wednesday, November 12, 2025Time: 10:40 a.m. ET Jefferies London Healthcare Conference Forum: 1&#215;1 Investor MeetingsDate: Monday, November 17, 2025 A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About EyePoint EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyePoint Announces Participation at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904001","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyePoint Announces Participation at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Announces Participation at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Guggenheim\u2019s 2 nd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: Monday, November 10, 2025Time: 10:30 a.m. ET Stifel 2025 Healthcare Conference Forum: Corporate PresentationDate: Wednesday, November 12, 2025Time: 10:40 a.m. ET Jefferies London Healthcare Conference Forum: 1&#215;1 Investor MeetingsDate: Monday, November 17, 2025 A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About EyePoint EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage &hellip; Continue reading &quot;EyePoint Announces Participation at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:26:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Announces Participation at Upcoming Investor Conferences\",\"datePublished\":\"2025-11-03T13:26:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/\"},\"wordCount\":398,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/\",\"name\":\"EyePoint Announces Participation at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=\",\"datePublished\":\"2025-11-03T13:26:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Announces Participation at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Announces Participation at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Announces Participation at Upcoming Investor Conferences - Market Newsdesk","og_description":"WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Guggenheim\u2019s 2 nd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: Monday, November 10, 2025Time: 10:30 a.m. ET Stifel 2025 Healthcare Conference Forum: Corporate PresentationDate: Wednesday, November 12, 2025Time: 10:40 a.m. ET Jefferies London Healthcare Conference Forum: 1&#215;1 Investor MeetingsDate: Monday, November 17, 2025 A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About EyePoint EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage &hellip; Continue reading \"EyePoint Announces Participation at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:26:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Announces Participation at Upcoming Investor Conferences","datePublished":"2025-11-03T13:26:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/"},"wordCount":398,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/","name":"EyePoint Announces Participation at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=","datePublished":"2025-11-03T13:26:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjI1NSM3MjM2OTE4IzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Announces Participation at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904001"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}